Observational studyTherapeutic advances in respiratory disease
Higher risk of viral infections in chronic obstructive pulmonary disease patients recovering from sepsis compared to non-sepsis patients: a propensity score-matched observational study.
Observational study in Therapeutic advances in respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with chronic obstructive pulmonary disease (COPD) who survive sepsis remain immunocompromised and are at increased risk of subsequent viral infections, including influenza and respiratory syncytial virus (RSV).
objectiveThis study aimed to address the 1-year risk of viral infections after sepsis in patients with COPD through the use of a federated database, TriNetX.
designA propensity score-matched (PSM) retrospective cohort study.
methodsWe used data of 903,683 COPD patients and identified 113,589 who experienced sepsis. The risk of distinct viral infections, including herpes simplex virus (HSV), varicella-zoster virus (VZV), cytomegalovirus (CMV), RSV and influenza, within 1 year post-sepsis was analyzed, with the employment of PSM to minimize confounding. The effect of vaccination was also assessed to determine its protective efficacy.
resultsA total of 98,883 COPD patients with sepsis and 1:1 matched COPD without sepsis were eligible for analyses. COPD patients with sepsis had consistently higher risk for viral infections within 1 year after the sepsis compared with COPD patients without sepsis. The hazard ratios (HRs) were as follows: HSV 1.936 (95% CI: 1.775-2.112), VZV 3.050 (2.489-3.737), CMV 2.101 (1.832-2.410), RSV 3.297 (3.158-3.443), and Influenza 3.197 (3.071-3.328). Sensitivity analysis demonstrated the consistently elevated risks across sepsis with varying severities. We further explored the protective effect of vaccinations among patients with COPD and found the significant protective effect of VZV glycoprotein E (HR 0.724, 95% CI: 0.595-0.882), RSV prefusion F protein-based vaccine (HR 0.676, 95% CI: 0.563-0.812) and influenza vaccine (HR 0.709, 95% CI: 0.649-0.776).
conclusionCOPD patients recovering from sepsis remain at increased risk of viral infections, highlighting the importance of targeted preventive strategies, including vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.